铝碳酸镁片联合莫沙必利治疗胆汁反流性胃炎疗效的Meta分析  

Meta Analysis of Hydrotalcite Tablets Combined with Mosapride for Treating Bile Reflux Gastritis

作　　者：谢日升 曾光 

机构地区：[1]广东省阳春市中医院,广东阳江529600

出　　处：《中国药业》2016年第7期27-30,共4页China Pharmaceuticals

摘　　要：目的利用循证医学方法,系统评价铝碳酸镁片联合莫沙必利治疗胆汁反流性胃炎的疗效及上腹部饱胀不适缓解率。方法通过计算机检索中文数据库,收集铝碳酸镁片联合莫沙必利片治疗胆汁反流性胃炎临床研究。按纳入及排除标准筛选文献,由2位评价者筛选文献、提取资料并行方法学质量评价,数据分析采用Revman 5.1软件,通过检验异质性,并根据异质性结果选择相应的效应模型,最后绘制漏斗图评定有无发表偏倚。结果治疗组临床治疗有效率[RR=1.20,95%CI(1.15,1.25)]、上腹饱胀不适缓解率[MD=-0.38,95%CI(-0.71,-0.05)]方面均优于对照组,两组差异均有统计学意义。结论现有证据表明,铝碳酸镁片联合莫沙必利在治疗胆汁反流性胃炎上有一定疗效。Objective To systematically evaluate the efficacy and improvement of bloating remission rate of Hydrotalcite Tablets combined with mosapride in the treatment of bile reflux gastritis. Methods The data of the Chinese database were retrieved for clinical trials of hydrotalcite combined with mosapride in treating bile reflux gastritis. According to inclusion and exclusion criteria,2 reviewers performed the screening,data extraction,and methodological quality assessment. Revman 5. 1 software was used to perform data analysis,by checking the heterogeneity and heterogeneity of the results based on selection the corresponding effects model,to finally draw the funnel for assessing whether the publication bias. Results According to the results of meta- analyses, the trial groups were better than the control groups in terms of overall efficacy [ RR = 1. 20,95% CI： 1. 15,1. 25 ],rate of bloating remission [ MD =- 0. 38,95% CI：- 0. 71,- 0. 05 ],with statistically significant difference. Conclusion The results show that Hydrotalcite Tablets combined with mosapride is effective in the treatment of bile reflux gastritis. However,there is a moderate risk of bias due to methodological quality problems in all 11 included RCTs. More strictly- designed,large- scale,high- quality,multi- centered RCTs are needed to confirm this result.

关 键 词：铝碳酸镁片 莫沙必利 胆汁反流性胃炎 META分析 

分 类 号：R969.4[医药卫生—药理学] R975[医药卫生—药学]